日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

PR1肽疫苗可诱导特异性免疫,并在髓系恶性肿瘤中产生临床反应。

Qazilbash, M H; Wieder, E; Thall, P F; Wang, X; Rios, R; Lu, S; Kanodia, S; Ruisaard, K E; Giralt, S A; Estey, E H; Cortes, J; Komanduri, K V; Clise-Dwyer, K; Alatrash, G; Ma, Q; Champlin, R E; Molldrem, J J

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

在异基因预处理方案中加入苯达莫司汀可改善慢性淋巴细胞白血病患者的长期预后。

Khouri, I F; Sui, D; Jabbour, E J; Samuels, B I; Turturro, F; Alatrash, G; Anderlini, P; Ahmed, S; Oran, B; Ciurea, S O; Marin, D; Olson, A; Patel, K K; Popat, U R; Ledesma, C; Kadia, T M; Ferrajoli, A; Burger, J A; Jorgensen, J L; Medeiros, L J; Bassett, R L; Gulbis, A M

Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

8F4(一种 T 细胞受体样抗 PR1/HLA-A2 抗体)在体内对原发性人类 AML 的活性

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You M J, Gagea M, Ma Q, Molldrem J J